西班牙10110例妊娠中早孕期联合筛查对早产子痫前期的筛查性能
在西班牙五个地区八家胎儿医学单位开展前瞻性队列研究,纳入10110例单胎妊娠,于孕11-13周采用FMF竞争风险模型联合母体特征、MAP、UtA-PI和PlGF筛查早产子痫前期。在10%固定筛查阳性率下,早产子痫前期检出率为72.7%(95%CI 62.9-82.6%),模型校准良好。
要点
- 早产子痫前期发生率0.7%(72/10110)。
- 联合母体特征、MAP、UtA-PI和PlGF筛查早产子痫前期,10%筛查阳性率下检出率72.7%。
- 以PAPP-A替代PlGF的三联试验检出率较低,为66.5%。
核心结论
- FMF模型在西班牙人群孕11-13周预测早产子痫前期有效,该方法可在常规临床实践中实施,但应辅以稳健的审计和监测系统以保持高质量筛查。
研究设计与样本
- 前瞻性队列研究,2017年9月至2019年12月在西班牙五个地区八家胎儿医学单位开展,纳入10110例单胎妊娠。
主要发现
- 早产子痫前期组与无子痫前期组相比,MAP MoM和UtA-PI MoM中位数显著较高,血清PlGF MoM和PAPP-A MoM中位数显著较低。
- 子痫前期孕妇中,所有生物标志物偏离正常的程度与分娩孕周呈负相关。
- 联合母体特征与病史、MAP、UtA-PI和PlGF筛查早产子痫前期,在10%筛查阳性率下检出率为72.7%(95%CI 62.9-82.6%)。
- 以PAPP-A替代PlGF的三联试验筛查早产子痫前期性能较差,检出率为66.5%(95%CI 55.8-77.2%)。
- 校准图显示预测风险与观察到的早产子痫前期发生率一致性良好,斜率为0.983(95%CI 0.846-1.120),截距为0.154(95%CI -0.091至0.397)。
关键数值与推荐
- 筛查阳性率固定为10%,早产子痫前期检出率72.7%(95%CI 62.9-82.6%)。
- 以PAPP-A替代PlGF后检出率66.5%(95%CI 55.8-77.2%)。
临床怎么用
- FMF模型可在常规临床实践中实施用于孕11-13周早产子痫前期筛查,但应辅以稳健的审计和监测系统以保持高质量筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the diagnostic accuracy of the Fetal Medicine Foundation (FMF) competing-risks model, incorporating maternal characteristics, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and placental growth factor (PlGF) (the 'triple test'), for the prediction at 11-13 weeks' gestation of preterm pre-eclampsia (PE) in a Spanish population. METHODS: This was a prospective cohort study performed in eight fetal medicine units in five different regions of Spain between September 2017 and December 2019. All pregnant women with a singleton pregnancy and a non-malformed live fetus attending a routine ultrasound examination at 11 + 0 to 13 + 6 weeks' gestation were invited to participate. Maternal demographic characteristics and medical history were recorded and MAP, UtA-PI, serum PlGF and pregnancy-associated plasma protein-A (PAPP-A) were measured following standardized protocols. Treatment with aspirin during pregnancy was also recorded. Raw values of biomarkers were converted into multiples of the median (MoM), and audits were performed periodically to provide regular feedback to operators and laboratories. Patient-specific risks for term and preterm PE were calculated according to the FMF competing-risks model, blinded to pregnancy outcome. The performance of screening for PE, taking into account aspirin use, was assessed by calculating the area under the receiver-operating-characteristics curve (AUC) and detection rate (DR) at a 10% fixed screen-positive rate (SPR). Risk calibration of the model was assessed. RESULTS: The study population comprised 10 110 singleton pregnancies, including 72 (0.7%) that developed preterm PE. In the preterm PE group, compared to those without PE, median MAP MoM and UtA-PI MoM were significantly higher, and median serum PlGF MoM and PAPP-A MoM were significantly lower. In women with PE, the deviation from normal in all biomarkers was inversely related to gestational age at delivery. Screening for preterm PE by a combination of maternal characteristics and medical history with MAP, UtA-PI and PlGF had a DR, at 10% SPR, of 72.7% (95% CI, 62.9-82.6%). An alternative strategy of replacing PlGF with PAPP-A in the triple test was associated with poorer screening performance for preterm PE, giving a DR of 66.5% (95% CI, 55.8-77.2%). The calibration plot showed good agreement between predicted risk and observed incidence of preterm PE, with a slope of 0.983 (95% CI, 0.846-1.120) and an intercept of 0.154 (95% CI, -0.091 to 0.397). CONCLUSIONS: The FMF model is effective in predicting preterm PE in the Spanish population at 11-13 weeks' gestation. This method of screening is feasible to implement in routine clinical practice, but it should be accompanied by a robust audit and monitoring system, in order to maintain high-quality screening. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Cuenca-Gómez D, de Paco Matallana C, Rolle V, et al. Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain. Ultrasound Obstet Gynecol. 2023. PMID: 37099759. doi:10.1002/uog.26233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。